Cardio Diagnostics (NASDAQ:CDIO) rose 11.68% on June 23, 2026, as AI diagnostics interest drove speculative micro-cap demand, with shares closing at $2.20.

Key Highlights

  • Rose 11.68%: Cardio Diagnostics closed at $2.20 on June 23 after moving $0.23 per share.
  • Catalyst: During the session, AI diagnostics interest drove speculative micro-cap demand.
  • Company: Cardio Diagnostics develops AI-supported cardiovascular tests based on DNA methylation and epigenetic data.
  • Session: The stock finished at $2.20, while the available company record showed a disclosed catalyst for the move.

Cardio Diagnostics (NASDAQ:CDIO) rose 11.68% on June 23, 2026, closing at $2.20 after a $0.23 per-share move. The session’s advance came as AI diagnostics interest drove speculative micro-cap demand, based on the available company disclosures and trading context.

No major same-day SEC filing was identified. Investor interest in the AI- and epigenetics-based cardiovascular testing platform continued to attract speculative buying in the micro-cap cardiac diagnostics space.

Cardio Diagnostics develops AI-supported cardiovascular tests based on DNA methylation and epigenetic data.

Cardio Diagnostics develops DNA methylation-based tests for cardiovascular disease risk assessment. The company has limited revenues and no formal guidance, making its share price highly reactive to sector-level interest in AI diagnostics themes.

The June 23 move did not follow a second earnings release during the session. Instead, the stock continued to reflect information from the earlier financial update, including the revenue, guidance or operating indicators described by the company.

The $2.20 close placed the shares 11.68% above the prior session. The available record did not show a separate change to the previously issued outlook on June 23.

For the June 23 close, the defining facts were the 11.68% advance, the $2.20 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.